Tuesday, July 8, 2025 7/8/2025

NOVEL A2A ADENOSINE AGONISTS IN VASCULAR PROTECTION

Award Number: R44HL065759
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2000
PERIOD OF PERFORMANCE END DATE: 08/31/2006

Group Awards By:

View Award Description

NOVEL A2A ADENOSINE AGONISTS IN VASCULAR PROTECTION - DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs). The nanoporous stent coating will be refined for optimal delivery of two drugs and provided by Setagon, Inc. The goal of this proposal is to demonstrate that the combined used of two synergistic anti-inflammatory compounds, ATL146e, an agonist of A2A adenosine receptors, and rolipram, a type IV phosphodiesterase (PDE) inhibitor, loaded into a proprietary nanoporous stent coating, inhibits stent restenosis in pigs more effectively than current state-of-the-art polymeric stent coatings. If these experiments are successful our plan is to develop the ATL146e/rolipram stent as a new product. ATL146e and rolipram are both approved for use in man and Adenosine Therapeutics has issued patents for the combined use of these compounds to prevent restenosis. Aim 1 proposes to investigate the elution kinetics of ATL146e and rolipram from stents into blood in vitro. In this aim we also will determine the terminal disposition half-life of ATL146e and rolipram in pigs using liquid chromatography/ mass spectroscopy of compounds extracted from pig blood after intravenous administration. Based on these data we will load stents with compounds sufficient to achieve free blood concentrations of only 1 ng/kg, that are unlikely to produce side effects. Aim 2 proposes to examine restenosis in pigs of stents loaded with ATL146e+/- rolipram. The results will be compared to commercially available stents containing sirolimus as a gold standard. Since ATL146e and rolipram have both been approved for human use, we anticipate that if the results of this study show that ATL146e +/- rolipram is more effective that sirolimus, it will be possible to initiate phase II clinical trials to test ATL146e/rolipram stents in man.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2005 ( Subtotal = $811,648 )
2005	2005	ADENOSINE THERAPEUTICS, LLC	PO BOX 4632	CHARLOTTESVILLE	VA	22905	CHARLOTTESVILLE CITY	USA	Cardiovascular Diseases Research	000	3	8/29/2005	NON-COMPETING CONTINUATION	$811,648
														Subtotal = $811,648

Issue Date FY: 2004 ( Subtotal = $624,818 )
2004	2004	ADENOSINE THERAPEUTICS, LLC	PO BOX 4632	CHARLOTTESVILLE	VA	22905	CHARLOTTESVILLE CITY	USA	Cardiovascular Diseases Research	000	2	9/17/2004	COMPETING CONTINUATION	$624,818
														Subtotal = $624,818

Grand Total All Awards = $1,436,466

Top

All Categories

About

Search

Reports

Data Submission

Award Information

NOVEL A2A ADENOSINE AGONISTS IN VASCULAR PROTECTION

Award Number: R44HL065759

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2000

PERIOD OF PERFORMANCE END DATE: 08/31/2006

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer